• J Boetto, C Birzu, M Kalamarides, M Peyre, and M Sanson.
• Département de neurochirurgie, hôpital Gui-de-Chauliac, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34090 Montpellier, France; CRICM INSERM U1127 CNRS UMR 7225, institut du cerveau, Paris, France. Electronic address: j-boetto@chu-montpellier.fr.
• Rev Med Interne. 2022 Feb 1; 43 (2): 98-105.

AbstractMeningiomas are the most frequent among intracranial tumors, and represent more than 30% of primitive central nervous system neoplasms. Arising from the meninges, they are generally benign lesions and can be treated by either radio-clinical follow-up or surgical resection with excellent outcome. However, more than 20% of meningiomas harbor atypical or malignant features and represent challenges for both prognostic evaluation and therapeutic strategy. The discovery of the genetic and epigenetic landscapes of meningiomas enabled the identification of new prognostic markers and potential therapeutic targets for refractory meningiomas. This review summarizes current epidemiology, histological and molecular characteristics, diagnosis and treatments for meningiomas, and highlights the close relationship between the development of meningiomas and hormonal intake, as illustrated by recent recommendations of the "Agence Nationale de Securité du Medicament", the French national drug safety agency.Copyright © 2021 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

21 keywords...

hide…